Richard Gallagher, MD, Professor of Clinical Psychiatry at New York Medical College and also a faculty member of the Columbia University Psychoanalytic Center, discusses best practices in treating schizophrenia. He describes the treatment of schizophrenia with optimal therapy with an individual focus. Maintenance treatment can often be at a somewhat lower dose, but compliance can be a problem.
Related Reading
Acetylcholinesterase Inhibitors (AChEI’s) for the treatment of visual hallucinations in schizophrenia: a case report.
Patel SS, Attard A, Jacobsen P, Shergill S. BMC Psychiatry. 2010 Sep 7;10:68.
Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.
Volonteri LS, Cerveri G, De Gaspari IF, Baldi ML, Rolandi ML, Papa P, Mauri MC, Mencacci C. Psychopharmacology (Berl). 2010 Jul;210(4):489-97. Epub 2010 Apr 27.
Current schizophrenia drugs: efficacy and side effects.
Krebs M, Leopold K, Hinzpeter A, Schaefer M. Expert Opin Pharmacother. 2006 Jun;7(8):1005-16. Review.
Sponsored by The Doctor’s Channel
